# Diabetes Research Hub — Monitor Report
**Run date:** 2026-10-05 (automated review; no existing files modified)

**Headline:** The 10-04 pipeline ran (all key files refreshed 10-04). Clinical-trial registry is flat day over day. The valuable signal is in PubMed: several high-tier papers on key therapies landed 09-29 to 10-01. The tracker is now 80 days stale and the gap ranking is still saturated. [Certain: programmatic diffs of snapshots 09-30, 10-03, 10-04.]

## File System Status
| File | Last modified | Status |
|---|---|---|
| hub_monitor_report.md | 2026-10-04 | Fresh (1 day) |
| clinical_trials_latest.json (906 trials) | 2026-10-04 | Fresh |
| pubmed_recent_latest.json (161 papers) | 2026-10-04 | Fresh |
| literature_gap_data.json / literature_gap_report.md | 2026-10-04 | Fresh |
| Diabetes_Research_Tracker.xlsx | 2026-07-17 | **STALE: 80 days** |
| hub_monitor.py flag | — | 876 live result files >14 days old (mostly audit/cache JSON) |

## Clinical Trial Changes
- 10-03 → 10-04: new 0, removed 0, status changes 0, new results 0. [Certain]
- 09-30 → 10-04 (weekly view): 4 added, 5 removed, 3 changed.
  - Added: NCT06109311 (Lilly orforglipron T2D, Phase 3, COMPLETED, results posted 2026-10-01), NCT06156696 (Astellas), NCT05120544 (Duke), NCT07849725 (not yet recruiting, eHealth).
  - Status change: **NCT07817251 (Novo CagriSema, switching from semaglutide) NOT_YET_RECRUITING → RECRUITING.**
  - Completion-date shifts: NCT07112872 (2026-11-27 → 2028-02-05, a 14-month slip), NCT06783504.
  - Removed (likely query drift, not withdrawals): NCT06272136, NCT06709729, NCT06600776, NCT06621030, NCT06587087.
- 57 Phase 3 RECRUITING trials in the snapshot. 10 are Vertex/Lilly/Novo: NCT06832410, NCT04786262 (VX-880/zimislecel); NCT07222137, NCT07222332 (baricitinib T1D); NCT07613307 (orforglipron); NCT06739122 (dulaglutide pediatric); NCT07797335 (zenagamtide); NCT07564414, NCT07282613, NCT07817251 (CagriSema).
- Sana: only NCT05791201 (Phase 1/2, ACTIVE_NOT_RECRUITING).
- Recently posted results worth a look: NCT06109311 and NCT06045221 (orforglipron vs semaglutide, 2026-09-15), NCT05872620 (orforglipron, 2026-09-04), NCT06370715 (LY900014, 2026-09-28). Evidence level: registry results are unreviewed. Keep them BRONZE until tied to a verified paper.

## PubMed Highlights (161 papers, 17 domains, 30-day lookback)
- Sample, not census: 1,023 matched, 161 read (15.7%). `domain_retmax=10`, so volume trends can't be measured. HIGH-activity domains by matched count: AI/ML 171, GLP-1 165, Microbiome 130, Biomarker 105.
- 14 new papers and 10 dropped since 10-03. Only 1 new cross-domain: 42827747 (tongue hyperspectral imaging × microbiota; AI/ML × Microbiome). It is low relevance. 24 cross-domain papers in total.
- Highest-value cross-domain carry-over: 42824926 (renal tissue microbiota/metabolites in DKD; Biomarker × Microbiome × Multi-Omics) fits the Tier 1 Multi-Omics area.
- **Key-therapy papers from the top journals** (titles only; evidence level unreviewed until abstracts are read):
  - 42810372 Lancet 09-29: retatrutide TRIUMPH-2 (obesity + T2D).
  - 42814954 NEJM 09-29: retatrutide for obesity.
  - 42815506 Lancet 09-30: orforglipron CV safety vs insulin glargine in T2D.
  - 42822480 Lancet Diabetes Endocrinol 10-01: low-dose IL-2 in new-onset T1D, DIABIL-2 phase 2b.
  - 42823485 Nature Medicine 10-01: semaglutide and kidney disease in T2D (RCT).
  - 42810355 Lancet D&E 09-29: petrelintide ZUPREME 1.
  - 42520060 Diabetes Care 10-01: fulminant HLH after teplizumab (case report; safety signal, low evidence level).
  - 42720752, 42767751: teplizumab pediatric, carried over.
- Key-therapy 30-day counts: zimislecel 0, orforglipron 14, retatrutide 10, CagriSema 3, teplizumab 7, baricitinib 2, finerenone 39.
- Islet field: 42608595 (Diabetologia, belatacept + sirolimus multicentre islet transplant), 42821872 (IPITA summit on stem cell-derived islets). Both relate to the VX-880 watch.

## Gap Analysis Summary
Top 5 (22 of 435 pairs tie at a score of 100.0, so the order is tie order, not signal):
1. Beta Cell Regen × Health Equity (0 joint)
2. Insulin Resistance × Islet Transplant (1)
3. Autoimmunity T1D × Nephropathy DKD (0; expected 8,371)
4. Islet Transplant × GWAS/Polygenic (0)
5. Islet Transplant × Personalized Nutrition (0)

- Islet Transplant (255 pubs) and LADA (616) are small domains, so keyword mismatch likely inflates their gaps. [Likely]
- Literature Synthesis & Gap Analysis is a Tier 1 area (RESEARCH_DOCTRINE.md). A saturated score is a method defect, not a finding. To move this from Likely to Certain, recompute with an observed/expected ratio and CI, and use a synonym-expanded query for Islet Transplant and LADA.

## Breaking News (web)
Standard searches ("diabetes breakthrough October 2026", "FDA diabetes approval October 2026") returned only low-quality results (fundraiser pages, conference PDFs, mid-2026 recaps). Nothing verifiable on Phase 3 readouts or FDA actions in the last 7 days. [Guessing: snippets only.] A "5 FDA decisions for primary care from September 2026" listing (patientcareonline) exists but was not opened. No escalation.

## Recommended Actions
1. Update Diabetes_Research_Tracker.xlsx (80 days stale): NCT07817251 now RECRUITING, NCT06109311 results posted, NCT07112872 completion slip.
2. Read abstracts of 42810372 (TRIUMPH-2), 42815506 (orforglipron CV safety), 42822480 (DIABIL-2), 42823485 and verify PMIDs before any claim; these are first-tier evidence for the ledger.
3. Review 42520060 (teplizumab HLH) against the teplizumab safety claims in Research_Findings_Summary.md.
4. Fix gap scoring (observed/expected + CI), then run: `python project1_literature_gap_analysis.py`.
5. Raise `domain_retmax` in `baseline_pubmed_alerts.py` if you want real volume trends; sort `intervention_types` in `baseline_clinical_trials.py` to stop false-positive diffs.
6. Manually check NCT05757713 (Sanofi teplizumab pediatric); not confirmed in the registry pull.
